Synlogic, Inc. Stock price

Equities

SYBX

US87166L2097

Biotechnology & Medical Research

Delayed Nasdaq 03:58:17 2024-03-27 pm EDT 5-day change 1st Jan Change
1.78 USD 0.00% Intraday chart for Synlogic, Inc. +2.89% -53.77%
Sales 2024 * 263K Sales 2025 * 4.48M Capitalization 20.73M
Net income 2024 * -24M Net income 2025 * -43M EV / Sales 2024 * -25.3 x
Net cash position 2024 * 27.4M Net cash position 2025 * 67.4M EV / Sales 2025 * -10.4 x
P/E ratio 2024 *
-0.71 x
P/E ratio 2025 *
-0.46 x
Employees 6
Yield 2024 *
-
Yield 2025 *
-
Free-Float 87.73%
More Fundamentals * Assessed data
Dynamic Chart
1 week+2.89%
Current month-6.81%
1 month-5.82%
3 months-50.42%
6 months-57.47%
Current year-53.77%
More quotes
1 week
1.73
Extreme 1.73
1.80
1 month
1.70
Extreme 1.7
2.04
Current year
1.55
Extreme 1.55
5.12
1 year
1.55
Extreme 1.55
10.64
3 years
1.55
Extreme 1.55
68.10
5 years
1.55
Extreme 1.55
150.15
10 years
1.55
Extreme 1.55
345.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 44 18-09-30
Director of Finance/CFO 43 18-05-31
General Counsel - 21-06-30
Members of the board TitleAgeSince
Director/Board Member 72 17-08-27
Chairman 71 17-08-27
Director/Board Member 64 12-09-30
More insiders
Date Price Change Volume
24-03-27 1.78 0.00% 3,111
24-03-26 1.78 -1.11% 16,711
24-03-25 1.8 0.00% 31,704
24-03-22 1.8 +2.86% 126,586
24-03-21 1.75 +1.16% 37,106

Delayed Quote Nasdaq, March 27, 2024 at 03:58 pm EDT

More quotes
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. It designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
1.78 USD
Average target price
1 USD
Spread / Average Target
-43.82%
Consensus
  1. Stock
  2. Equities
  3. Stock Synlogic, Inc. - Nasdaq